AllSci News
Azitra secures US patent for ATR-12 engineered microbiome therapy targeting Netherton syndrome
A new US patent covering an engineered live biotherapeutic for Netherton syndrome was awarded to Connecticut-based Azitra, Inc. (NYSE American: AZTR). As…
Catalyst Pharmaceuticals resolves final US patent litigation, securing FIRDAPSE market exclusivity through January 2035
A negotiated patent settlement on Firdapse (amifampridine) between Catalyst Pharmaceuticals and Hetero Labs Ltd. has closed the last open front in amifampridine…
Rigel acquires Veppanu from Arvinas and Pfizer for USD 85m upfront
Rigel Pharmaceuticals (Nasdaq: RIGL) is acquiring exclusive global rights to Veppanu (vepdegestrant), the first US FDA-approved oral PROTAC, in a deal that...
Kelun-Biotech's PD-1 x VEGF bispecific antibody receives China IND clearance
China's regulatory clearance for SKB118 marks a dual-jurisdiction entry into clinical development for a PD-1 x VEGF bispecific antibody that is already...
Insilico Medicine and Ribo collaborate on AI-guided RNA interference and oligonucleotide therapeutics development
A new platform collaboration positions generative AI drug discovery infrastructure at the center of RNA interference therapeutics development, as Insilico Medicine and…
Cerevance closes USD 20 million Series C as Phase III Parkinson's trial reaches full enrollment
Cerevance's Phase III Parkinson's trial reaches full enrollment as USD 20 million Series C extends runway
Deep Mind spin out Isomorphic Labs secures USD 2.1b Series B to scale AI drug design engine
A USD 2.1 billion Series B round positions London-based Isomorphic Labs as one of the most heavily capitalized AI-native drug design companies in the world,...
20/20 BioLabs licenses PSA velocity algorithm from University of South Carolina for cancer detection
20/20 BioLabs licenses a PSA velocity algorithm from the University of South Carolina, adding a longitudinal biomarker analysis tool to its multi-cancer...
Army Medical University demonstrates hepatic APOE3 Christchurch gene therapy reduces Alzheimer's pathology in Neuron
Researchers at Army Medical University (Third Military Medical University) in Chongqing, China report that liver-directed delivery of the APOE3 Christchurch...
Brainomix and Boehringer Ingelheim expand e-Lung AI collaboration for pulmonary fibrosis diagnosis
Data on earlier pulmonary fibrosis diagnosis has pushed Brainomix and Boehringer Ingelheim to expand their collaboration, moving from retrospective...
Sironax’s SARM1 allosteric inhibitor gains FDA Fast Track status for chemotherapy-induced peripheral neuropathy
There are no approved treatments for chemotherapy-induced peripheral neuropathy (CIPN), a condition affecting a substantial proportion of cancer patients receiving neurotoxic regimens…
Bristol Myers Squibb signs USD 15.2b deal with Hengrui for 13 early-stage oncology, hematology programs
Bristol Myers Squibb (NYSE: BMY) is committing up to USD 950 million in near-term structured payments to access a portfolio of 13 early-stage programs from...
Inhibrx's OX40 agonist doubles response rates in head and neck cancer trial
Interim INBRX-106 Phase 2 data show a near doubling of confirmed response rates over pembrolizumab alone in a high-PD-L1 head and neck cancer population,...
Boehringer Ingelheim licenses preclinical anti-inflammatory antibody program from Immunitas for EUR 407.5m
Boehringer Ingelheim has licensed a preclinical antibody program from Immunitas Therapeutics, a Waltham, Massachusetts-based precision immunotherapy...
CEL-SCI raises USD 7.2m in public offering to fund Multikine cancer immunotherapy development
A pattern of recurring equity raises at Vienna-based CEL-SCI Corporation reflects the cash demands of a pre-revenue clinical-stage company advancing a...
The AllSci Brief
Free, systematic R&D and deal news. Daily.